Metis Global Partners LLC Has $39.74 Million Holdings in Eli Lilly and Company $LLY

Metis Global Partners LLC lessened its position in Eli Lilly and Company (NYSE:LLY) by 4.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 52,086 shares of the company’s stock after selling 2,315 shares during the quarter. Eli Lilly and Company makes up about 0.9% of Metis Global Partners LLC’s holdings, making the stock its 14th biggest holding. Metis Global Partners LLC’s holdings in Eli Lilly and Company were worth $39,742,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Lazard Freres Gestion S.A.S. increased its position in Eli Lilly and Company by 114.3% in the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after purchasing an additional 41,222 shares during the last quarter. Exencial Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 189.6% during the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock valued at $13,283,000 after buying an additional 11,396 shares during the last quarter. Rede Wealth LLC bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $487,000. Central Pacific Bank Trust Division increased its holdings in Eli Lilly and Company by 25.8% in the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after buying an additional 1,843 shares during the last quarter. Finally, Oak Family Advisors LLC acquired a new position in Eli Lilly and Company in the third quarter worth approximately $1,979,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Robust fundamentals and guidance — Lilly reported a strong Q4 beat and raised FY2026 outlook, underscoring surging GLP‑1/weight‑loss revenue and underpinning investor optimism. How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report
• Positive Sentiment: Pre‑launch inventory build — Lilly filed that it has about $1.5 billion of pre‑launch inventory for its experimental oral weight‑loss pill, signaling management confidence in commercialization and readiness to capture market share if approved. Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
• Positive Sentiment: M&A to expand pipeline — Lilly agreed to acquire Orna Therapeutics for up to $2.4B, adding an RNA platform that diversifies growth beyond GLP‑1s and supports longer‑term R&D optionality. Eli Lilly to acquire ‘world’s most innovative biotech startup’ for up to $2.4B
• Positive Sentiment: Analyst upgrades & institutional buying — recent upgrades (Freedom Capital to strong‑buy) and a stake increase by Fisher Asset Management reinforce buy‑side conviction. Zacks / analyst coverage
• Neutral Sentiment: Industry tailwinds from AI and biotech momentum — broader analyst pieces highlight AI drug‑discovery and biotech sector strength that could benefit Lilly longer term, but these are thematic rather than company‑specific catalysts. 2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off
• Neutral Sentiment: Market commentary and price forecasts — multiple outlets publish bullish multi‑year forecasts and “reasons to buy” writeups; useful for sentiment but speculative for near‑term price moves. Stock Price Prediction and Forecast 2026-2030
• Negative Sentiment: Regulatory binary risk — the April FDA decision on the oral weight‑loss pill is binary and could trigger significant volatility; the large pre‑launch build increases both upside on approval and downside on rejection or delays. Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision
• Negative Sentiment: Competitive dynamics — Novo Nordisk remains a dominant competitor in obesity drugs; market‑share battles, pricing pressure or faster rival launches could blunt Lilly’s growth trajectory. Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market

Eli Lilly and Company Trading Up 2.3%

Eli Lilly and Company stock opened at $1,038.59 on Friday. The business’s 50-day simple moving average is $1,051.78 and its 200-day simple moving average is $904.70. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The firm has a market capitalization of $981.86 billion, a PE ratio of 45.25, a PEG ratio of 1.18 and a beta of 0.39. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 112.50% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same period in the previous year, the business posted $5.32 EPS. The company’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 26.14%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research note on Monday, February 2nd. TD Cowen increased their target price on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Thursday, January 29th. Daiwa Securities Group set a $1,230.00 target price on Eli Lilly and Company and gave the company a “buy” rating in a report on Tuesday, December 16th. Finally, Bank of America decreased their price target on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research note on Monday, December 15th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,217.71.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.